PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 20–20 | Cite as

Nivolumab plus ipilimumab improves QOL versus sunitinib

Clinical study


  1. Cella D, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology : 15 Jan 2019. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations